



Drug Discovery

An International Journal

FDA Approved Drugs – January 2016

Vidhya V

Publication History

Received: 10 May 2016

Accepted: 22 May 2016

Published: April-June 2016

Citation

Vidhya V. FDA Approved Drugs – January 2016. *Drug Discovery*, 2016, 11(28), 21-22

Publication License



© The Author(s) 2016. Open Access. This article is licensed under a Creative Commons Attribution License 4.0 (CC BY 4.0).

General Note



Article is recommended to print as digital color version in recycled paper.

ONZETRA XSAIL (SUMATRIPTAN NASAL POWDER)

Company: Avanir; Approved by January 2016

Specific Treatments: migraine

General Information

Onzetra Xsail is specifically indicated for the acute treatment of migraine with or without aura in adults. It is supplied as a powder for intranasal administration, delivered with the Xsail breath-powered delivery device only. The recommended dose is 22 mg, administered by use of one nosepiece (11 mg) in each nostril. The maximum dose in a 24-hour period should not exceed two doses (44 mg) separated by at least 2 hours.

Mechanism of Action

Onzetra Xsail is a nasal powder formulation of sumatriptan, a serotonin 5-HT_{1B/1D} receptor agonist. Sumatriptan binds with high affinity to human cloned 5-HT_{1B/1D} receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine

Vidhya V,

FDA Approved Drugs – January 2016,

Drug Discovery, 2016, 11(28), 21-22,

© The Author(s) 2016. Open Access. This article is licensed under a Creative Commons Attribution License 4.0 (CC BY 4.0)

headache through agonist effects at the 5-HT_{1B/1D} receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of proinflammatory neuropeptide release.

Side Effects

Adverse effects associated with the use of Onzetra Xsail may include: abnormal taste, nasal discomfort, rhinorrhea, rhinitis

ZEPATIER (ELBASVIR AND GRAZOPREVRIR)

Company: Merck; Approved by January 2016

Specific Treatments: chronic HCV genotypes 1 or 4

General Information

Zepatier is specifically indicated with or without ribavirin for the treatment of chronic HCV genotypes 1 or 4 infection in adults. It is supplied as a tablet for oral administration. Recommended dosage: One tablet taken orally once daily with or without food. Please see drug label for dosage regimens and durations for patients with Genotype 1 or 4 HCV with or without cirrhosis.

Mechanism of Action

Zepatier is a fixed-dose combination product containing elbasvir, a hepatitis C virus (HCV) NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor.

Side Effects

Adverse effects associated with the use of Zepatier may include: fatigue, headache, nausea, anemia.